Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep:110:154300.
doi: 10.1016/j.metabol.2020.154300. Epub 2020 Jun 20.

Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients

Alessandro Santaniello  1 , Barbara Vigone  2 , Lorenzo Beretta  3
Affiliations
Comment

Letter to the editor: Immunomodulation by phosphodiesterase-4 inhibitor in COVID-19 patients

Alessandro Santaniello et al. Metabolism. 2020 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare no conflict of interest.

Comment on

References

    1. Dalamaga M., Karampela I., Mantzoros C.S. Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19 [published online ahead of print, 2020 Jun 1] Metabolism. 2020;109:154282. doi: 10.1016/j.metabol.2020.154282. - DOI - PMC - PubMed
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648. [published online ahead of print, 2020 Feb 24] - DOI - PubMed
    1. Tay M.Z., Poh C.M., Rénia L., MacAry P.A., LFP Ng. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020:12. doi: 10.1038/s41577-020-0311-8. [published online ahead of print, 2020 Apr 28] - DOI - PMC - PubMed
    1. Schafer P.H., Parton A., Gandhi A.K. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855. doi: 10.1111/j.1476-5381.2009.00559.x. - DOI - PMC - PubMed
    1. Imam F., Al-Harbi N.O., Al-Harbi M.M. Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries. Int Immunopharmacol. 2019;66:260–266. doi: 10.1016/j.intimp.2018.11.023. - DOI - PubMed

Substances